Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.57 |
| ▸ | BRD2 | P25440 | 9/20 | 0.57 |
| ▸ | BRD3 | Q15059 | 9/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.57 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.57 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CCL2 | P13500 | 1/20 | 0.57 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.57 |
| ▸ | TACR1 | P25103 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.57 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.57 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.57 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18249949 | 0.90 | BRD4 (0.48) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL11909203 | 0.90 | BRD4 (0.55) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16619338 | 0.90 | BRD4 (0.55) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18249910 | 0.89 | BRD4 (0.43) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18249934 | 0.89 | BRD4 (0.43) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18249962 | 0.88 | BRD4 (0.43) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL12096364 | 0.88 | BRD4 (0.62) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL1907655 | 0.88 | BRD4 (0.62) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL1902577 | 0.84 | CYP3A4 (0.69) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL1904697 | 0.84 | CYP3A4 (0.69) | BRD4CYP3A4CYP2C9BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699573-B1 | 7-(3,5-DIMETHYL-4-ISOXAZOLYL)-8-(METHYLOXY)-1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2699573-B1 | 7-(3,5-DIMETHYL-4-ISOXAZOLYL)-8-(METHYLOXY)-1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2017-05-31 | — | — | EP | disclosed |
| WO-2016186453-A1 | QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | KAINOS MEDICINE, INC. (KR) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016186453-A1 | QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | KAINOS MEDICINE, INC. (KR) | 2016-11-24 | — | — | WO | disclosed |
| WO-2015049629-A1 | IMIDAZOQUINOLINE COMPOUNDS AS BROMODOMAIN INHIBITORS | Piramal Enterprises Limited (IN) | 2015-04-09 | — | — | WO | disclosed |
| US-8846709-B2 | 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1H-imidazo[4,5-C]quinoline derivatives | GLAXOSMITHKLINE LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846709-B2 | 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1H-imidazo[4,5-C]quinoline derivatives | GLAXOSMITHKLINE LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846709-B2 | 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1H-imidazo[4,5-C]quinoline derivatives | GLAXOSMITHKLINE LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140045834-A1 | 7-(3,5-Dimethyl-4-Isoxazolyl)-8-(Methyloxy)-1H-Imidazo[4,5-C]Quinoline Derivatives | GLAXOSMITHKLINE LLC (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045834-A1 | 7-(3,5-Dimethyl-4-Isoxazolyl)-8-(Methyloxy)-1H-Imidazo[4,5-C]Quinoline Derivatives | GLAXOSMITHKLINE LLC (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045834-A1 | 7-(3,5-Dimethyl-4-Isoxazolyl)-8-(Methyloxy)-1H-Imidazo[4,5-C]Quinoline Derivatives | GLAXOSMITHKLINE LLC (US) | 2014-02-13 | — | — | US | disclosed |
| EP-2496576-B1 | IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8557984-B2 | Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120232074-A1 | Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-09-13 | — | — | US | disclosed |
| EP-2496576-A1 | IMIDAZO [4, 5-C]QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline LLC (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011054846-A1 | IMIDAZO [4, 5-C] QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045834-A1 | 7-(3,5-Dimethyl-4-Isoxazolyl)-8-(Methyloxy)-1H-Imidazo[4,5-C]Quinoline Derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT2B7, UGT1A7 | BRD4 5/4885CYP3A4 45/4885CYP2C9 1133/4885 |
| US-20120232074-A1 | Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors | BRD4, BRD3, BRPF3 | BRD4 1/4885CYP3A4 1579/4885CYP2C9 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.